ARUP LABORATORIES | www.aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: (801) 583-2787, toll free: (800) 522-2787
Julio C. Delgado, MD, MS, Director of Laboratories

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	2/3/1974
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	

Factor XIII (F13A1) V34L Variant

ARUP test code 2003220

Factor XIII Variant Specimen	Whole Blood
Factor XIII (F13A1) V34L Variant	Heterozygous

Indication for testing: Assess genetic risk for thrombosis.

HETEROZYGOUS: One copy of the Factor XIII (F13A1), V34L sequence variant was detected. In Caucasians, this genotype is associated with a decreased risk for pulmonary embolism and deep vein thrombosis, a modest risk reduction for myocardial infarction and a slight decrease in coronary artery disease.

Recommendations: This result should be interpreted in the context of clinical and other laboratory findings as thrombotic risk is influenced by other genetic and non-genetic factors not assessed by this assay. If clinically indicated, testing for other inherited or acquired thrombophilic disorders is recommended; consider DNA testing for the factor V Leiden mutation, measurement of total plasma homocysteine concentration, serological assays for anticardiolipin antibodies and multiple phospholipid-dependent coagulation assays for lupus inhibitor.

This result has been reviewed and approved by Hunter Best, Ph.D.

H=High, L=Low, *=Abnormal, C=Critical

Background Information: Factor XIII (F13A1) V34L Variant

Characteristics: The Factor XIII (F13A1), V34L sequence variant is a protective factor against pulmonary embolism, deep vein thrombosis, and myocardial infarction in Caucasians. It may also have a slight protective effect against coronary artery disease. Limited data suggests the V34L sequence variant may also be associated with idiopathic spontaneous subconjunctival hemorrhage (SSH), but this finding has not been confirmed.
Allele Frequency: Caucasian 0.27, African American 0.17, American Indian 0.29, Asian 0.01.
Inheritance: Autosomal dominant.
Cause: Homozygosity or heterozygosity for F13A1; V34L
Variant Tested: F13A1 c.103G>T; p.Val34Leu.
Clinical Sensitivity: Varies by ethnicity.
Methodology: Polymerase chain reaction and fluorescence monitoring.
Analytical Sensitivity and Specificity: 99 percent
Limitations: Mutations in the F13A1 or F13B genes, other than the V34L sequence variant, are not evaluated. Diagnostic errors can occur due to rare sequence variations.
The protective effect of the V34L sequence variant has not been established for ethnicities other than Caucasian and may be altered by other genetic and non-genetic factors not assessed by this assay.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement C: aruplab.com/CS

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Factor XIII Variant Specimen	18-145-126887	5/25/2018 10:24:00 AM	5/26/2018 10:53:41 PM	5/29/2018 3:47:00 PM
Factor XIII (F13A1) V34L Variant	18-145-126887	5/25/2018 10:24:00 AM	5/26/2018 10:53:41 PM	5/29/2018 3:47:00 PM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical